FDA Goes Too Far in GDUFA II Draft Guidance, AAM Says

Drug Industry Daily
A A
An FDA policy proposal on expedited generic drug approvals runs counter to the goals of the program and breaks faith with the upcoming GDUFA II agreement with the industry, generic drugmakers said.

To View This Article:

Login

Subscribe To Drug Industry Daily